Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

Aromatase inhibitors are able to block the biosynthesis of estrogen—a process that is essential in bone maturation, growth-plate fusion, and cessation of longitudinal growth. Aromatase ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for HR-positive, HER2-negative metastatic breast cancer that also has one or more ...

Early initiation of moderate-intensity aerobic exercise during aromatase inhibitor use reduced pain and prevented pain increases among postmenopausal women with breast cancer. Early initiation of ...

But she notes that researchers still don't know which strategy works best: taking an aromatase inhibitor instead of tamoxifen, as the first course of therapy after surgery for breast cancer ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

The Fuqua laboratory has determined that the K303R mutation alters many aspects of hormone action, including binding to co-regulatory proteins, enhanced stability, estrogen hypersensitivity, response ...